AER-271
Severe Acute Ischemic Stroke (Large Hemispheric Infarction)
Phase 1Active
Key Facts
Indication
Severe Acute Ischemic Stroke (Large Hemispheric Infarction)
Phase
Phase 1
Status
Active
Company
About Aeromics
Aeromics is pioneering a novel approach to treating cerebral edema by inhibiting aquaporin-4 water channels, based on foundational research recognized by the Nobel Prize. Its lead program, AER-271, is in Phase 1 development for severe acute ischemic stroke, with a planned Phase 2 trial targeting patients with Large Hemispheric Infarction. The company is privately held, backed by venture capital and NIH grants, and is positioned to potentially deliver the first therapy specifically designed to prevent brain swelling in stroke, a condition responsible for significant morbidity and mortality.
View full company profile